Aldeyra Therapeutics (ALDX) Share-based Compensation (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Share-based Compensation for 14 consecutive years, with $9.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 7.83% year-over-year to $9.3 million; the trailing twelve-month figure through Jun 2026 stood at $9.3 million (up 7.83% YoY), and the FY2025 full-year result was $8.6 million, up 7.64% from the prior year.
• Share-based Compensation slipped to $9.3 million in Q2 2026 per ALDX's latest filing, from $10.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $10.0 million in Q1 2026 and bottomed at -$800341.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $6.1 million across 5 years, with a median of $6.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 128.37% in 2023, then soared 257.85% in 2024.
• Over 5 years, Share-based Compensation stood at $2.8 million in 2022, then sank by 128.37% to -$800341.0 in 2023, then jumped by 257.85% to $1.3 million in 2024, then declined by 13.71% to $1.1 million in 2025, then soared by 751.24% to $9.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $9.3 million, $10.0 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.